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Abstract
Mechanical circulatory support (MCS) devices provide both short and long term hemodynamic support for advanced heart
failure patients. Unfortunately these devices remain plagued by thromboembolic complications associated with chronic
platelet activation – mandating complex, lifelong anticoagulation therapy. To address the unmet need for enhancing the
thromboresistance of these devices to extend their long term use, we developed a universal predictive methodology
entitled Device Thrombogenicity Emulation (DTE) that facilitates optimizing the thrombogenic performance of any MCS
device – ideally to a level that may obviate the need for mandatory anticoagulation. DTE combines in silico numerical
simulations with in vitro measurements by correlating device hemodynamics with platelet activity coagulation markers –
before and after iterative design modifications aimed at achieving optimized thrombogenic performance. DTE proof-of-
concept is demonstrated by comparing two rotary Left Ventricular Assist Devices (LVADs) (DeBakey vs HeartAssist 5,
Micromed Houston, TX), the latter a version of the former following optimization of geometrical features implicated in
device thrombogenicity. Cumulative stresses that may drive platelets beyond their activation threshold were calculated
along multiple flow trajectories and collapsed into probability density functions (PDFs) representing the device
‘thrombogenic footprint’, indicating significantly reduced thrombogenicity for the optimized design. Platelet activity
measurements performed in the actual pump prototypes operating under clinical conditions in circulation flow loops –
before and after the optimization with the DTE methodology, show an order of magnitude lower platelet activity rate for the
optimized device. The robust capability of this predictive technology – demonstrated here for attaining safe and cost-
effective pre-clinical MCS thrombo-optimization – indicates its potential for reducing device thrombogenicity to a level that
may significantly limit the extent of concomitant antithrombotic pharmacotherapy needed for safe clinical device use.
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Introduction
Congestive heart failure, the final common pathway of all forms
of heart disease, has reached epidemic proportions in the United
States and in many nations around the world. Over 5.7 million
patients suffer from heart failure in the US, with the number of
patients expected to grow by 50% over the next 15 years [1]. In
the spectrum of heart failure severity, approximately 100,000
patients a year are afflicted with AHA/ACC Class D, NYHA
Class IV disease. These patients have such reduced ventricular
systolic function that they need a pump, either as an assist device
or as a replacement. Mechanical circulatory support (MCS)
devices, i.e. ventricular assist devices (VADs) and the total artificial
heart (TAH), offer this pump therapy, either as a bridge to
eventual heart transplantation or as an alternative to transplan-
tation [2]. While life saving, the current devices have many
limitations, including the propensity for thrombosis and throm-
boembolism, often introducing clinical sequelae that further
increases the healthcare burden to the patient and society.
Recipients of VADs and mechanical heart valves (MHVs) are
often faced with the requirement of a lifetime of complex and risky
anticoagulation regimens. Although the current generation of
MCS devices shows a vast improvement in hemodynamic
performance over their predecessors, reducing flow-induced
thrombogenicity still remains a major challenge and this could
drastically change through development of a new generation of
devices that are optimized to be thromboresistant (i.e., with a
reduced need for antithrombotic therapy).
The high incidence of thromboembolic events in MCS devices
occurs largely due to non-physiological flow past constricted
geometries within a device, where platelets, the principal cellular
clotting elements in blood, are exposed to elevated shear stresses
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32463and exposure times [3]. Platelets activated by this mechanism are
considered one of the major culprits in attempting to modulate the
hemostatic response in MCS devices, even in the absence of
contact activation and/or chemical agonists [4]. Although the
threshold for shear induced platelet activation has been established
based on constant stress experiments (i.e., Hellum’s criterion
[4,5]), it should be noted that under physiological conditions of
flow through devices, platelets are exposed to varying shear stress
levels, turbulent stresses [6], longer residence times in pathological
flow regions (hot-spots), as well as repeated passages through the
device that may precipitate activation [3], aggregation, and free
emboli formation.
Presently hemodynamic studies employed for device optimiza-
tion during the R&D stage have significant limitations as follows:
(a) They utilize experimental flow visualization and/or traditional
computational fluid dynamics (CFD) mostly concentrating on
mapping regions of high shear stresses with no direct correlation to
thrombogenic markers. (b) Most of them do not resolve the
intricate, small-scale, flow phenomena and their interaction with
blood-borne particulates such as platelets which initiate device
thrombogenicity (i.e., drive platelets past the activation threshold
as discussed above). (c) These methods do not map specific stress
loading histories that platelets experience along their correspond-
ing flow trajectories. As such, they cannot be utilized for
identifying and eliminating thrombogenic hot-spots within the
devices and are therefore mostly applied ad hoc. (d) There is no
iterative synergy between numerical and experimental methods
and this significantly limits device thromboresistance optimization.
To address the above limitations, we have developed a
methodology – Device Thrombogenicity Emulation (DTE) that
bridges this gap by integrating the pertinent hemodynamics with
the corresponding thrombogenic markers – facilitating for the first
time an actual optimization of the thromboresistance performance.
DTE offers a paradigm shift by integrating state-of-the-art
numerical and experimental approaches in silico and in vitro (rather
than in vivo). This facilitates optimizing the device during the R&D
phase. The optimization process is performed first in silico – in the
modeling domain (in which virtual design modifications are
examined) – followed by experimental emulation of the device
specific stress loading histories (waveforms) in vitro in which the
resultant platelet activity is measured. The process is iterated till
optimization (i.e., thrombogenicity minimization) is achieved. The
optimized design prototype is built and tested by comparing its
thrombogenic performance to that before the optimization. A
detailed description of the methodology appears in Materials and
Methods.
To demonstrate a proof-of-concept of the DTE methodology
applied to an actual device, we took and redesigned a
representative VAD (a rotary blood pump design) that had
checkered history of thrombogenic complications which affected
the overall clinical results [7,8]. With DTE, we show that an order
of magnitude reduction in thrombogenicity can be achieved with
this VAD, and that the redesigned prototype may be suitable for
implantation with the possibility that its recipients may benefit
from a significantly reduced need for pharmacologically complex
antithrombotic therapy.
Materials and Methods
Device Thrombogenicity Emulation (DTE)
A schematic of DTE is shown in Figure 1, illustrating
application to a ventricular assist device (VAD). The optimization
process is performed first in silico – in the modeling domain –
followed by experimental emulation of the device specific stress
loading histories (waveforms) in a Hemodynamic Shearing Device
(HSD; Figure 1 – top-right) [9]) where device specific effects on
platelet activation are measured with a modified prothrombinase
assay (Figure 1, top-left) [10]. The features and advantages of this
assay are described in the Experimental Flow Loop and Platelet
Activation Measurement section. Flow past the VAD is modeled
with a high fidelity two-phase FSI (fluid-structure interaction)
simulation resolving all components of the stress tensor that are
relevant to flow-induced thrombogenicity and subsequently
tracking down and capturing the loading history of platelets in
the flow field along trajectories that may drive them beyond the
activation threshold. An example of platelet trajectories in the flow
Figure 1. Schematic of the Device Thrombogenicity Emulation (DTE). (bottom-left) Representative platelet trajectories in the flow field of a
ventricular assist device (debakey VAD); (bottom-right) Emulation of stress-loading history of typical platelet trajectories in the hemodynamic
shearing device (HSD); (top-right) Computer-controlled HSD where platelets are exposed to uniform shear stress; (top-left) Principle of the modified
prothrombinase assay used to measure the activity state of platelets sampled from the HSD.
doi:10.1371/journal.pone.0032463.g001
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histories of these four platelet trajectories (computed with the
combined effect of shear stress and exposure time [3,5,11]) is
shown in Figure 1 (bottom-right). Typically, several thousand of
such loading histories are collapsed into a quantitative probability
density function (PDF) – a thrombogenic footprint of the device
[12,13] that maps where the cumulative stress of each trajectory
will end up in the distribution of the stress accumulation range of
the device. To validate this in silico approach experimentally,
extreme cases of platelet stress loading trajectories termed as hot-
spot trajectories are extracted and tested in the HSD and platelet
activity is quantified for these trajectories with a modified
prothrombinase assay [10] (Figure 1; top-left). Virtual design
modifications to the original device geometry or its components
can then be performed and above in silico and experimental
process iterated in the virtual domain to map the least
thrombogenic footprint of the redesigned device. The prototype
device design is then frozen and prototypes are manufactured
according to their optimized specifications. Comparative throm-
bogenicity experiments of the original and optimized prototypes
(whole devices) are then performed in vitro to confirm that the
reduction in thrombogenicity with DTE methodology was
achieved in the optimized device prototype.
Blood Pumps
We tested two rotary pump device prototypes – the DeBakey
TM
VAD and the redesigned optimized version of this device – the
HeartAssist 5
TM. Both prototypes were provided by the same
manufacturer (Figure 2A; top-right; MicroMed Cardiovascular
Inc., Houston, TX) for experimental measurements in addition to
the 3D prototype geometries for numerical simulations. The basic
pump features and control unit are described in detail elsewhere
[14]. Briefly, the main components of the DeBakey VAD
(Figure 2A; top-left) – include a stationary flow straightener, an
inducer-impeller with an integrated electric motor rotor (moving
unit), a stationary diffuser, and motor stator housing. The
following design features, illustrated in Figure 2B and Figure 2C,
were modified between the original and the optimized VAD: (A)
Inlet flow straightener vanes: Four orthogonal vanes in the original
design were replaced with three vanes, 120u apart. (B) Inlet and
outlet hub and bearing taper: The back-step front hub between the
flow straightener and the inducer-impeller was tapered and
streamlined as indicated to eliminate flow stagnation and
backflow, and the outlet hub was retrofitted with ball-in-cup
bearing to minimize recirculation in the impeller-diffuser interface.
(C) Impeller: The impeller blade leading edge, profiles, length,
pitch, and pitch-angle (which direct the flow into the inducer-
impeller) were modified.
Computational Grid and Simulation Procedure
Fluid structure Interaction (FSI) simulations were conducted
using Unsteady Reynolds Averaged Navier-Stokes (URANS) for
25 impeller revolutions to solve blood flow through both VAD
geometries. Blood was modeled as a two-phase fluid [15] (platelets
considered as neutrally buoyant solid spherical particles of 3 mm
diameter) with a density of 1,081 kg/m
3 and a viscosity of
0.0035 kg/m.s. A rotational speed of 9,500 rpm and a flow rate of
4 L/min, corresponding to most commonly encountered clinical
operating conditions, were used for both simulations. Highly
resolved hexahedral computational grids (3.68 million elements)
were generated in HEXPRESS (Numeca International, CA) to
achieve a boundary layer sublayer (y+=1; corresponding to the
nearest boundary element height of 10 mm) necessary for the two
equation k-v [16] turbulence model as part of the URANS.
Details of the mesh are shown in Figure 3 with the finely resolved
boundary layer shown in inset. The Fluent CFD solver (Ansys Inc.,
Lebanon, NH) was used for this calculation and an optimized time
step of 7.0610
25 s was selected per iteration and corresponds to a
4-degree change in the rotor position. 4,000–5,000 platelets were
injected from a plane at the tip of the inlet flow straightener. The
simulation approach is further described in detail in our previous
publications [12,13].
Figure 2. Design changes in Debakey VAD for reducing thrombogenicity. (A) (left) Components of the Original Debakey VAD; (right)
Original (Debakey) and Optimized (HeartAssist 5) VAD prototypes. (B) Design differences in the inlet and outlet region are illustrated for both VADs.
(C) Design differences in the impeller region are illustrated for both VADs.
doi:10.1371/journal.pone.0032463.g002
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Stress loading history of the seeded platelets along trajectories
was computed by incorporating the combined effect of stress and
exposure time [5]. The stress tensor was extracted from the
simulations along the corresponding platelet trajectories and
rendered into a scalar stress value, as previously described [12,13],
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so that both viscous and turbulent stresses (tij) are considered in
the SA formulation. A linear product of instantaneous values of the
stress, s, and exposure time, texp was assumed [3,13] for the stress
accumulation (SA) and a summation of this instantaneous product
values is carried out according to:
SA~s|texp~
ð texp
t0
s(t)dt&
X N
i~1
si|Dt: ð2Þ
where si, i~1,2,:::,N, is the nodal scalar value extracted from the
total stress tensor described above, Dt is the corresponding time
step between successive nodal points, and the resulting SA units
are in Pa.s. While other models of stress accumulation argue for
various power law combinations in the form of
P
sa|Dt
b, this
model seems to predict platelets stress accumulation in devices
better, and was recently validated with platelet activation
measurements in channels [17], as well as by our previous work
[3,13].
Probability Density Function (PDF) of Stress
Accumulation
To account for the large number of platelets flowing along
multiple trajectories in a complex flow field such as flow within a
VAD, we have used a robust statistical technique (applied by us
recently to compare and optimize MHV designs [12,13]) to
collapse this information into a quantity that could be used for
comparing the thrombogenic potential of different VAD designs.
This approach computes the statistical distribution of stress
accumulation (based on SA ranges) along the multiple trajectories
(the probability density function – PDF) and is therefore used as a
surrogate for evaluating the overall thrombogenic potential of each
VAD (a thrombogenic ‘footprint’ of the VAD design). To compare
the statistical distribution of stress accumulations of different
platelet populations that were used in the various simulations
(4,000–5,000), while guaranteeing that the percentage activation is
independent of variations in the number of seeded particles and
spatiotemporal variations, we have interpolated between the
smaller and larger populations’ statistical distributions by applying
bootstrapping statistics [12,13] to guarantee that PDFs from the
different population sizes are compatible and comparable. The
mean value and standard deviation for each statistical distribution
(PDF) for both the overall VAD designs and in regions of interest
specific to design changes: (A) Inlet flow straightener (vanes), (B)
Inlet hub and bearing taper, (C) Impeller, and (D) Impeller-shroud
near wall region and tip-shroud gap clearance, are reported in the
results.
Experimental Flow Loop & Platelet Activation
Measurement
A flow-loop that generates physiological range of cardiac
outputs (3–6 L/min) as a function of pump speed (RPM) and
pressure (DP) was built (Figure 4). The flow loop consists of two
Tygon R3603 tubes – a 0.5 inch ID flow tube connected to the
VAD and a 0.25 inch ID flow resistor. A cardiac output of 4 L/
min which represents the average physiological condition was
chosen. This corresponded to an impeller speed of 9500 RPM for
both pumps, which is within the clinical operating range for
continuous flow VADs.
Citrated blood (120 ml) was obtained from healthy adult
volunteers (n=10) who have abstained from all medication,
including aspirin, for at least two weeks prior to blood donation,
after obtaining written and informed consent (protocol approved
by Stony Brook University IRB) prior to venipuncture. Gel-filtered
platelets were prepared and diluted (15610
6/ml) in modified
Tyrode’s buffer. Red blood cells were purified with Histopaque
1119 (Sigma, St. Louis, MO) and diluted to 800610
6/ml in
modified Tyrode’s buffer. Platelets or platelets with red blood cells
(120 ml) were recirculated in a physiological flow loop for 30 min
that generates a pressure rise across the pump of ,70–80 mm Hg
as described above. Platelet activation was measured with a
modified prothrombinase Platelet Activity State (PAS) assay
[9,10], from timed samples at t=0, 10, 20, 30 min. The key
advantage of using acetylated prothrombinase in our assay is that
an acetylated form of thrombin is generated – which cleaves the
chromogenic substrate identically to native thrombin – but is
otherwise incapable of causing any feedback activation into the
coagulation cascade (Figure 1 – top-left). Therefore, we establish a
1:1 correlation between the shear stresses generated by the device
(the agonist that activates platelets in this case) and the thrombin
(the more relevant and universal coagulation marker) generation
by the activated platelets. Platelet activation was normalized to
maximum activation determined by sonication [9] and was
Figure 3. Hexahedral mesh configurations (,3.7 million
elements) for FSI simulations generated with HEXPRESS. Note
refinement at the boundary layers (inset).
doi:10.1371/journal.pone.0032463.g003
Figure 4. Flow loop schematic for conducting platelet activa-
tion measurements in the two VADs. A flow-resistor of identical
lengths is used for both VADs to produce physiological pressure rise
across the VADs.
doi:10.1371/journal.pone.0032463.g004
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infer pair-wise differences in slope of the fitted lines (Platelet
Activation Rate, PAR) between the original and optimized VAD
design.
Results
We report results from the numerical modeling of the two
VADs followed by experimental measurements of platelet activity
performed in the two VAD prototypes. The results have been
reported in the following order: First, numerical modeling results
of the two VADs are illustrated by the velocity vector flow field
(freeze frames from FSI modeling) and platelet dispersion
patterns before and after optimization. This is followed by
detailed analysis of stress accumulation for thousands of platelet
trajectories (designated as PDFs) that pass through the entire
VADs (overall PDFs) and specific problematic regions of the
VADs (region specific PDFs). We have illustrated specific
examples of platelet trajectories and flow fields in both VADs
that show optimization was indeed achieved. Following the
numerical results, we report experimental platelet activation
measurements performed in both VAD prototypes and the strong
confirmatory correspondence to numerical findings indicating an
order of magnitude lower thrombogenicity in the optimized
VAD.
Improved Platelet Dispersion in Optimized VAD
A general depiction of the flow fields (platelet dispersion patterns
superimposed on the velocity vector field) is shown in Figure 5A
(top: original VAD; bottom: optimized VAD) at the mid-cross
section in both VADs. This demonstrates how the new streamlined
tapered rear hub with blood flow incoming through the 3 blade
stator vanes eliminates the problem of the original design in which
the inflow through the 4 blade stator was impinging against the hub
shoulder and stagnating in that region. The platelet dispersion
patterns showing transition from the inlet flow straightener to the
inducer-impeller region are further illustrated in Figures S1 and S2
(original VAD (top); optimized VAD (bottom)). This demonstrates
that the new impeller design with a steeper pitch (blade angle of
attack) generates more favorable flow conditions that are less
activating to the platelets, additionally indicating that the ‘time of
flight’ of the platelets is shorter through the optimized design –
reducing the duration plateletsareexposedto elevated shear stresses
(quantitative details appear in the PDF analysis below).
Lower Overall Stress on Platelets in Optimized VAD
Stress accumulation (SA) was computed in both prototypes for
25 impeller rotations. The PDF was computed for an ensemble of
4,000–5,000 platelet trajectories passing through the two VAD
designs, and was extrapolated and recalculated for 40,000 and
Figure 5. Numerical Analysis of the VAD prototypes. (A) Flow fields at the mid-cross section in both VAD designs (top: original VAD; bottom:
optimized VAD). The platelet dispersion patterns (red) are superimposed on the velocity vector field in the mid cross-section. (B) Overall probability
density functions (PDF) of stress accumulation (SA) for both VADs (red – original design; blue – optimized design). The inset shows the statistical
distribution with its outliers.
doi:10.1371/journal.pone.0032463.g005
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relevant platelet count) by applying bootstrapping statistics
[12,13]. The resulting PDF of the SA ranges distribution (the
‘thrombogenic footprint’ of the device) is shown in Figure 5B. A
very significant shift (to the left) in the mean stress accumulation to
lower values (p,0.01) was observed with the optimized design
(mean SA 6 SD: 3.563.3 Pa.s), as compared to the original design
(mean SA 6 SD: 16.2614.4 Pa.s) – with the latter having a
broader distribution (low kurtosis and larger standard deviation),
thereby placing a very large number of platelets in the higher end
of the SA spectrum as compared to the optimized design.
Statistical analysis of PDFs and Outliers
Outliers in the statistical distributions that appear in Figure 5B
(inset) are often indicative either of measurement error or that the
population has a heavy-tailed distribution (like in our case, Log-
normal distributions). In the former case one wishes to discard them
or use statistics that are robust to outliers, while in the latter case
they indicate that the distribution has high kurtosis (representing a
very spiky distribution with a small standard deviation, similar to
ourdistributioninFigure5B– blue line)andthat one shouldbevery
cautious in using tools that assume a normal distribution (in our
analysis we have to use non-parametric statistics or transform the
Log-normal distributions to Normal distributions). The statistical
analysis indicates that the HeartAssist 5 distribution (blue line) in
Figure 5B has high kurtosis (mean SA 6 SD: 3.563.3 Pa.s) with a
heavy tail of outlier SA values. On the other hand, the original
DeBakey design (red line, Figure 5B) has a much broader
distribution with low kurtosis and larger standard deviation (mean
SA 6 SD: 16.2614.4 Pa.s). While the original DeBakey design
clearly has less ‘outliers’, its distribution places a staggering amount
of platelets in the higher end of the SA spectrum as compared to the
optimized design. The statistical tools used indicate that the
HeartAssist 5 distribution (blue line) has many outliers, but even
when considering the outliers in this distribution, the range of the
SA is much lower (highest SA value is approx. 40 Pa.s) than the
original DeBakey design (highest SA value is approx. 60 Pa.s), and
alsohasa muchlowermean value.However,theseoutlierSAvalues
could still lead to some undesirable platelet activation. Further
analysis could include case specific analysis of these outliers that can
be utilized for additional optimization of the VAD.
Design Modifications in Optimized VAD Increases its
Thromboresistance
To delineate the specific regions implicated in higher overall
thrombogenicity of the original and optimized VAD designs, we
compared mean stress accumulation distributions specific to
regions of design changes shown in Figure 2. Regions of Interest
(ROI) were identified corresponding to these design changes and
the PDFs of stress accumulation were calculated in these ROI (blue
boxed areas in Figure 6 – insets; left-right): inlet flow straightener,
inlet ball-in-cup bearing, impeller region, and impeller-shroud gap
and near shroud region. A significant shift in mean SA to lower
values was observed for the various ROI in all cases (Table 1).
Specifically, as a consequence of design modifications to the
impeller region, markedly fewer platelets were exposed to regions
of high stress accumulation (10–50 Pa.s) in the optimized VAD.
Similarly, the design optimization at the inlet flow straightener
reduced exposure time of platelets to high stresses and eliminated
flow stagnation that was observed in the original VAD design
(Figure 7-left and Figure S1). A similar modification at the
inducer-impeller interface depicted reduced recirculation and
smaller vortices as compared to the original VAD design (Figure 7-
right). Furthermore, in the optimized VAD design, fewer platelets
(84%) passed through the ROI close to the shroud wall and gap
between the impeller tip and the shroud (where the shear stresses
are the highest), as compared to 94% for the original VAD design.
Stress Loading Waveforms Extracted from Hot-Spot
Trajectories for DTE Experiments and their
Correspondence to PDFs
The significantly lower SA observed in the optimized design
PDF is further corroborated by analysis of typical hot-spot platelet
trajectories (ones that expose platelets to elevated shear stresses for
a duration that may activate them) during their passage through
the VADs, and their resultant stress loading waveforms that are
programmed into the HSD to emulate design dependent extreme
Figure 6. Design change ROI specific PDFs (left-right): inlet flow straightener, inlet hub and bearing, impeller, impeller tip-shroud
gap and near shroud region. The ROI are indicated by boxed areas (inset).
doi:10.1371/journal.pone.0032463.g006
Table 1. Mean (6 SD) of stress accumulation (SA) for platelet
trajectories passing though regions of interest (ROI) in original
and optimized VADs.
Design Change ROI Original VAD SA (Pa.s) Optimized VAD SA (Pa.s)
Impeller 27.1613.1 5.164.4
Impeller-Shroud gap 15.468.2 8.865.8
Flow Straightener 7.168.2 3.962.2
Hub and Bearing 8.869.3 4.162.3
Results correspond to PDFs shown for each ROI in Figure 6.
doi:10.1371/journal.pone.0032463.t001
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illustrates that platelets flowing through the original VAD
experience elevated stresses and longer exposure times, in contrast
to platelets flowing through the optimized design (Figure 8).
Representative platelet stress waveforms extracted from hot-spot
trajectories show that platelets flowing through the original VAD
(Figure 8A) experience elevated stresses (200–600 Pa) and longer
exposure times, in contrast to platelets flowing through the
optimized design (Figure 8B; peak stress below 200 Pa and
significantly lower exposure times to high stresses). For example,
platelet 2 (Figure 8A) is trapped at the impeller-inducer interface
and experiences the highest stress (,600 Pa). From these 4
trajectories that correspond to platelets flowing through the highest
shear stress regions (hot-spots), it is easy to infer that the stress
accumulation is substantially minimized for the optimized design.
This is further reiterated by the PDFs themselves that represent
the overall activation potential of the platelet bulk while passing
through the VAD (i.e., the statistical distribution of final stress
accumulation values reached in each of the multiple trajectories).
Order of Magnitude Lower Platelet Activation Rates
Measured in the Optimized VAD Prototype
Platelet activation was measured with the modified prothrom-
binase assay [10] in identical flow loops (Figure 4) for 30 min for
both VAD prototypes operating at: cardiac output (flow rate) of
4 L/min; pressure rise across the VADs of 70–80 mm Hg; and
impeller rotation speed of 9500 rpm, as described in Materials and
Methods. Experiments were conducted with platelets alone (n=10
donors) and then repeated with purified platelets and added
autologous red blood cells (RBC; n=5 donors). In both cases,
respectively, an order of magnitude reduction in Platelet Activity
Rates (PAR – the slope of the platelet activation linear fit) was
observed (3610
24 min
21 and 6610
24 min
21 for the original
VAD and 3610
25 min
21 and 6610
25 min
21 for the optimized
VAD – Figure 9A (platelets only) and Figure 9B (platelets and red
blood cells), p,0.01). This result was in full agreement with the
numerical results of the significant shift towards lower SA values
Figure 7. Velocity vectors (mid-plane) showing improved blood washing (reduced recirculation and stagnation) at the hub and
bearing interfaces at both inlet (left, straightener-impeller interface) and exit (right, impeller-diffuser interface) for original (top)
and optimized (bottom) VAD designs.
doi:10.1371/journal.pone.0032463.g007
Figure 8. Markedly reduced stress accumulation of platelet
trajectories in optimized VAD. Representative stress and exposure
time for 4 platelet trajectories during their passage through the (A)
original VAD (DeBakey) and (B) optimized VAD (HeartAssist 5) are
shown.
doi:10.1371/journal.pone.0032463.g008
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original design, as illustrated previously.
Discussion
In the NHLBI 2004 Working Group report for Next
Generation VADs for Destination Therapy, a major recommen-
dation was to develop improved antithrombotic therapies and
device technologies to reduce the vexing problem of thromboem-
bolic events, based on successful computational and experimental
fluid dynamic studies within prosthetic heart valves [18].
Following this critical recommendation, we developed and
validated the DTE methodology in pilot studies to demonstrate
the effect of sensitive design parameters on the thrombogenic
potential of components of MCS devices, as well as stand-alone
prosthetics (two bileaflet MHVs – the St. Jude Medical (SJM)
Regent MHV, and the ATS MHV). With DTE, it was
demonstrated that the ATS open pivot hinges offer a better
design solution than the SJM recessed hinges [13], and that the
ATS design can be significantly optimized further [12]. In this
study we have extended the application of the DTE methodology
to a complex MCS device – the rotary VAD, and demonstrated
the universal nature of this optimizing methodology for signifi-
cantly improving the thrombogenic performance of blood
recirculating cardiovascular devices.
Advantages of continuous flow blood pumps over pulsatile first
generation VADs, include miniaturized size, increased mechanical
durability and hemodynamic efficiency, reduced cost, and
improved bridge to transplant rates [19]. Previous studies on
thromboresistance optimization of such continuous flow VADs
have investigated the parametric effects of features such as:
impeller tip-shroud gap clearances [20,21], diffuser inlet angles
[22], geometric profiles of flow straightener, impeller and diffuser
[22,23,24], impeller-inducer (moving components of the VAD)
angular alignments and axial clearances and impeller rotation
rates [25] with CFD, particle image velocimetry and RBC
hemolytic testing methods. Significant limitations of these studies
as thromboresistance optimization tools are due to analyses
performed only in the numerical domain and/or conclusions
based on hemolysis damage models (hemolysis occurs at shear
levels one order of magnitude greater than those required to
activate platelets [26]). DTE, on the other hand is a comprehen-
sive and universal optimization strategy that offers direct
correlation with physical thrombosis and coagulation markers.
Its clear advantage over previous approaches is demonstrated in
the current application for VAD design optimization, where the
effects of specific design changes on platelet activation potential
are quantitatively analyzed and directly correlated to measured
thrombogenic markers.
The motivation for the design changes in the DeBakey VAD
stem from several preclinical and clinical studies conducted with
the initial VAD design [7,8,27,28,29,30] that identified thrombo-
genic regions (inlet hub and bearing and flow straighteners) within
the VAD. For instance, thrombus formation was observed in ex vivo
studies at the inlet hub and bearing interface and the inlet [7].
Corresponding design changes were made (Figure 2) to the above
components to reduce backflow, vortex formation and flow
stagnation, surface contact area with the blood, and to facilitate
a smoother transition from the straightener vanes to the inducer-
impeller region.
Stress-loading histories (waveforms), of platelets flowing through
distinct regions within the two VAD designs, were computed and
correlated with platelet activation measurements performed in the
two prototypes that quantify the overall device thrombogenicity.
The PDFs of the stress accumulation (‘thrombogenic footprint’ of
the overall device (Figure 5B)), as well as the PDFs of specific
regions of interest such as the inlet, the inlet hub-bearing interface,
the impeller, and the impeller-shroud gap near the shroud
(Figure 6), clearly indicate that the intended design changes
significantly reduced VAD thrombogenicity (design optimization
significantly shifted the SA distributions towards lower values, i.e.,
to a significantly reduced thrombogenic potential). The improved
hemodynamics of the optimized design are evident using more
traditional comparison of the flow fields of the two designs, which
depict the elimination of stagnation regions and improved washing
properties in the inlet and exit hub-bearing (Figure 7) of the
optimized VAD.
A closer examination of these improved hemodynamics patterns
is facilitated by the two-phase flow simulation that reveals and
quantifies the platelets dispersion patterns when flowing through
the devices (Figure S2). The number of platelets traversing the
Figure 9. Platelet activation measurements in VAD prototypes.
(A) Platelet Activation Rate (PAR) in the original and optimized VAD
prototypes measured in a flow-loop with the modified prothrombinase
assay (platelet experiments only, n=10, mean 6 SEM plotted for each
point) (B) Platelet Activation Rate (PAR) in the original and optimized
VAD prototypes measured in a flow-loop with the modified prothrom-
binase assay (platelets and red cells experiments, n=5, mean 6 SEM
plotted for each point). An order of magnitude lower platelet activation
rate-slope (PAR) is achieved by the optimized design in both cases.
doi:10.1371/journal.pone.0032463.g009
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in the optimized VAD design, translating to a significantly lower
number of platelets exposed to the higher stress loading along such
hot-spot trajectories.Thisclearlyindicatesthat the optimized design
entrains platelets towards the rotating core, away from the elevated
stresses regions of the gap clearance. The stress accumulation PDF
for the ROI in the gap between the rotor blade tip and the shroud
(housing) shows a 2-fold reduction in stress accumulation. This also
follows the overall 5-fold lower stress accumulation in the impeller
region (Figure 6) wherein a series of design changes significantly
reduces the platelet residencetime and surface contactarea, thereby
minimizing the peak stresses and exposure times. This is further
corroborated by the platelet stress waveforms extracted from hot-
spots trajectories comparing the original VAD (Figure 8A) with the
optimized VAD (Figure 8B), which very clearly demonstrate how
the optimization process resulted in far lower stress-exposure
conditions for platelets flowing in the optimized VAD.
Measurement of thrombin represents the actual contribution of
platelets to the coagulation cascade final product of blood clot
formation. Traditional platelet activation surface markers offer a
less universal marker as they point only to specific aspects of the
platelet activity – not necessarily to the clotting product (thrombin
cleaves soluble fibrinogen into insoluble fibrin – the building block
of blood clot formation). Our focus in this manuscript is to
illustrate a methodology applied to design optimization of a VAD
with the goal of minimizing the occurrence of pathological fluid
shear stresses that lead to platelet activation (eventually leading to
coagulation). In our experimental studies, we therefore use purified
blood platelets over whole blood or plasma experiments since with
the former choice we are able to isolate and measure the direct
effect of pathological shear induced damage on platelets and their
capacity to generate thrombin. This 1:1 correspondence measured
with the most relevant coagulation marker (thrombin) offers a
direct comparison between flow-induced thrombogenicity of
different device designs. This is therefore our method of choice
for measuring the thrombogenic potential of blood recirculating
devices, and our group established its validity over the years in
addition to successfully demonstrating a strong correspondence
between thrombin measured with the PAS method and between
platelet surface activation markers (P-selectin) [31].
While it is clear in the clinical domain that patients, for overall
clinical safety will remain on anticoagulants, i.e. Vitamin K
antagonists and antiplatelet medication, i.e. Aspirin (ASA), the
extent, complexity and dose of these regimens may very likely be
reduced using DTE. Reduction of the extent of antithrombotic
medication that a patient is required to take will also help reduce
the significant side effect burden associated with many of these
medications, e.g. gastrointestinal bleeding and hemorrhagic stroke.
This however is not the focus of our current study.
In summary, the efficacy and broad applicability of the DTE
methodology for achieving thromboresistance optimization of MCS
devices was demonstrated in this study in a complex MCS device —
a rotary VAD. The DTE proof-of-concept applicability was
established by comparing the thrombogenicity of a continuous flow
rotary VAD before and after optimization. Specifically, an order of
magnitude lower Platelet Activity Rate (PAR) was measured in the
optimized VAD prototype as compared to measurements in the
original VAD — correlating to the very significant overall shift in
the mean stress accumulation (SA) to lower values (the device
‘thrombogenic footprint’ predicted by the DTE).
The DTE optimization methodology described herein demon-
strates the use of advanced numerical simulations combined with
experimental techniques for quantifying measures that are directly
relevant to thrombosis and coagulation markers in devices. It
offers an unparalleled degree of freedom to test and redesign any
type of MCS device as it is device independent, i.e., it emulates the
device hemodynamics and enables measuring the resultant device
thrombogenicity without the need to build the redesigned
prototype first – rather following its optimization. It is envisioned
that the DTE approach will become essential in guiding the design
and enhancing the safety and effectiveness of many therapeutic
implant devices placed in the blood stream. In addition to
reducing R&D costs, DTE may prevent unfortunate situations in
which devices need to be recalled or clinical trials stopped, due to
unacceptable levels of clinical thromboembolic events – situations
which would be catastrophic to patients, with devastating financial
costs to device manufacturers and society as well. These savings
will ultimately be passed on to patients and will further aid in
reducing the escalating costs of healthcare.
Supporting Information
Figure S1 FSI simulation results showing platelet (red)
passage and velocity vector flow fields (mid cross-
section) in original (top) and optimized (bottom) VAD
prototypes.
(GIF)
Figure S2 Isometric view representation of platelet
(red) dispersion patterns in the original (top) and
optimized (bottom) VAD prototypes.
(GIF)
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